LYmphadenectomy After NeoAdjuvant Chemotherapy

Inclusion Criteria: * Age between 18 and 75 years * Patients affected by advanced ovarian cancer (FIGO stage III-IV) who underwent \> 2 to \<7 cycles of neoadjuvant chemotherapy based on platinum and taxanes. * Clinical response (instrumental and serological) complete or partial. * Residual intra-abdominal tumor \<1 cm. * Absence of disease macroscopically evident in lymph nodes (\> 1 cm) * Life expectancy of at least 4 weeks * ECOG PS ≤ 2 * Adequate respiratory function, hepatic, cardiac, bone marrow and renal function (creatinine clearance\> 60 mL / min according to the Cockroft formula) * Patient psychologically able to follow the study procedures Exclusion Criteria: * Patients with severe impairment of lung function, or liver failure, such as not to allow access in safety in the operating room. * Not epithelial ovarian neoplasms or borderline tumors * Other invasive cancer in the last 5 years or signs of recurrence or activity * Patients with intra-abdominal residual tumor\> 1 cm * Patients with the presence of bulky nodes (\> 1 cm) in the intra-operative evaluation * Diseases of the lymphatic system (including lymphatic edema of unknown origin)